Compare ASTRAZENECA PHARMA with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DISHMAN PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DISHMAN PHARMA ASTRAZENECA PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 91.0 25.1 362.6% View Chart
P/BV x 25.6 3.3 765.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
ASTRAZENECA PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278374 341.3%   
Low Rs883129 684.7%   
Sales per share (Unadj.) Rs228.4197.8 115.5%  
Earnings per share (Unadj.) Rs10.421.2 48.9%  
Cash flow per share (Unadj.) Rs16.334.7 46.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs98.8179.9 54.9%  
Shares outstanding (eoy) m25.0080.69 31.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.3 371.8%   
Avg P/E ratio x104.211.9 878.4%  
P/CF ratio (eoy) x66.47.2 916.7%  
Price / Book Value ratio x10.91.4 781.9%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m27,00820,306 133.0%   
No. of employees `0001.40.8 163.6%   
Total wages/salary Rs m1,5355,355 28.7%   
Avg. sales/employee Rs Th4,210.919,252.7 21.9%   
Avg. wages/employee Rs Th1,132.26,459.5 17.5%   
Avg. net profit/employee Rs Th191.12,064.1 9.3%   
INCOME DATA
Net Sales Rs m5,71015,961 35.8%  
Other income Rs m123265 46.2%   
Total revenues Rs m5,83316,226 35.9%   
Gross profit Rs m4634,103 11.3%  
Depreciation Rs m1471,091 13.5%   
Interest Rs m0944 0.0%   
Profit before tax Rs m4382,334 18.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179624 28.7%   
Profit after tax Rs m2591,711 15.1%  
Gross profit margin %8.125.7 31.5%  
Effective tax rate %40.826.7 152.8%   
Net profit margin %4.510.7 42.3%  
BALANCE SHEET DATA
Current assets Rs m3,20911,018 29.1%   
Current liabilities Rs m2,0709,517 21.7%   
Net working cap to sales %20.09.4 212.3%  
Current ratio x1.61.2 133.9%  
Inventory Days Days72110 65.5%  
Debtors Days Days3535 100.2%  
Net fixed assets Rs m79016,304 4.8%   
Share capital Rs m50161 31.0%   
"Free" reserves Rs m2,41912,907 18.7%   
Net worth Rs m2,46914,516 17.0%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m4,60529,805 15.5%  
Interest coverage xNM3.5-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.5 231.5%   
Return on assets %5.68.9 63.1%  
Return on equity %10.511.8 89.0%  
Return on capital %17.717.5 101.2%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m3004,952 6.0%   
Fx outflow Rs m2,015697 289.2%   
Net fx Rs m-1,7154,255 -40.3%   
CASH FLOW
From Operations Rs m882,786 3.2%  
From Investments Rs m-94-1,529 6.1%  
From Financial Activity Rs mNA-941 0.0%  
Net Cashflow Rs m-6316 -1.8%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.7 8.1%  
FIIs % 15.7 12.7 123.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 22.1 41.2%  
Shareholders   12,856 46,261 27.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  WOCKHARDT  VENUS REMEDIES  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; HCL Technologies & SBI Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a mixed note with stocks in the consumer durables sector.

Related Views on News

ASTRAZENECA PHARMA Surges by 5%; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Oct 23, 2019 | Updated on Oct 23, 2019

ASTRAZENECA PHARMA share price has surged by 5% and its current market price is Rs 2,543. The BSE HEALTHCARE is up by 0.5%. The top gainers in the BSE HEALTHCARE Index is ASTRAZENECA PHARMA (up 5.0%). The top losers are DR. REDDYS LAB (down 0.2%) and ERIS LIFESCIENCES LIMITED (down 0.3%).

ASTRAZENECA PHARMA at 52 Week High; BSE 500 Index Down 0.1 % (Market Updates)

Oct 23, 2019 | Updated on Oct 23, 2019

ASTRAZENECA PHARMA share price has hit a 52-week high. It is presently trading at Rs 2,470. BSE 500 Index is down by 0.1% at 15,036. Within the BSE 500, ASTRAZENECA PHARMA (up 2.4%) and ASTER DM HEALTHCARE LTD (up 5.8%) are among the top gainers, while top losers are RBL BANK LTD and DISH TV.

LAURUS LABS LTD Surges by 9%; BSE HEALTHCARE Index Up 0.2% (Market Updates)

Oct 23, 2019 | Updated on Oct 23, 2019

LAURUS LABS LTD share price has surged by 9% and its current market price is Rs 345. The BSE HEALTHCARE is up by 0.2%. The top gainers in the BSE HEALTHCARE Index are LAURUS LABS LTD (up 9.3%) and ASTRAZENECA PHARMA (up 6.0%). The top losers are ABBOTT INDIA (down 0.2%) and GLENMARK PHARMA (down 0.2%).

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Oct 23, 2019 03:22 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS